Trial Outcomes & Findings for Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System (NCT NCT03286543)
NCT ID: NCT03286543
Last Updated: 2021-05-12
Results Overview
All subjects were asked to complete daily diaries to record their average pain intensity while walking during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." For each subject, the mean score for each diary period was calculated and a mean of all four diary periods was calculated (weeks 1-4). The mean group scores for weeks 1-4 are reported.
COMPLETED
NA
47 participants
Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA)
2021-05-12
Participant Flow
Recruitment began in July 2017 (with first subject enrollment in September 2017) and was concluded in February 2020. Subjects were screened from the available pool of candidates scheduled to undergo a primary unilateral total knee replacement procedure.
After obtaining informed consent, subjects were evaluated for eligibility.
Participant milestones
| Measure |
Consented Subjects
Subjects who signed an informed consent form.
|
Treatment Group
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|---|
|
Consented
STARTED
|
47
|
0
|
0
|
|
Consented
Randomized
|
45
|
0
|
0
|
|
Consented
Enrolled
|
41
|
0
|
0
|
|
Consented
Intent to Treat Set
|
37
|
0
|
0
|
|
Consented
Per Protocol Set
|
23
|
0
|
0
|
|
Consented
COMPLETED
|
28
|
0
|
0
|
|
Consented
NOT COMPLETED
|
19
|
0
|
0
|
|
Study Enrollment
STARTED
|
0
|
18
|
23
|
|
Study Enrollment
Intent to Treat Set
|
0
|
18
|
19
|
|
Study Enrollment
Per Protocol Set
|
0
|
7
|
16
|
|
Study Enrollment
COMPLETED
|
0
|
12
|
16
|
|
Study Enrollment
NOT COMPLETED
|
0
|
6
|
7
|
Reasons for withdrawal
| Measure |
Consented Subjects
Subjects who signed an informed consent form.
|
Treatment Group
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|---|
|
Consented
Screen failure before randomization
|
2
|
0
|
0
|
|
Consented
Screen failure before enrollment
|
4
|
0
|
0
|
|
Consented
TKA cancelled after enrollment
|
1
|
0
|
0
|
|
Consented
Withdrawn from study
|
12
|
0
|
0
|
|
Study Enrollment
TKA cancelled after enrollment
|
0
|
0
|
1
|
|
Study Enrollment
Withdrawn from study
|
0
|
6
|
6
|
Baseline Characteristics
One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
Baseline characteristics by cohort
| Measure |
Treatment Group
n=18 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=23 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
Total
n=41 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Age, Categorical
Between 18 and 65 years
|
9 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
11 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
20 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Age, Categorical
>=65 years
|
9 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
11 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
20 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Age, Continuous
|
65.0 years
STANDARD_DEVIATION 5.5 • n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
63.0 years
STANDARD_DEVIATION 10.3 • n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
63.9 years
STANDARD_DEVIATION 8.4 • n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Sex: Female, Male
Female
|
12 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
12 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
24 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Sex: Female, Male
Male
|
6 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
10 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
16 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
1 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
1 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
18 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
21 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
39 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
1 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
3 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Race (NIH/OMB)
White
|
16 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
21 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
37 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Region of Enrollment
United States
|
18 participants
n=18 Participants
|
23 participants
n=23 Participants
|
41 participants
n=41 Participants
|
|
Affected Leg
Right Leg
|
8 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
15 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
23 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Affected Leg
Left Leg
|
10 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
7 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
17 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Reason for Total Knee Arthroplasty (TKA)
Osteoarthritis
|
16 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
21 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
37 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Reason for Total Knee Arthroplasty (TKA)
Post-Traumatic Arthritis
|
2 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
0 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
2 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
|
Reason for Total Knee Arthroplasty (TKA)
Degenerative Joint Disease
|
0 Participants
n=18 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
1 Participants
n=22 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
1 Participants
n=40 Participants • One Control Group subject withdrew after randomization due to their unwillingness to participate as a control, and Demographic information was not collected.
|
PRIMARY outcome
Timeframe: Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA)Population: Per Protocol Set
All subjects were asked to complete daily diaries to record their average pain intensity while walking during the past 24 hours on each day of a 7-day period using an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." For each subject, the mean score for each diary period was calculated and a mean of all four diary periods was calculated (weeks 1-4). The mean group scores for weeks 1-4 are reported.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Average Knee Pain While Walking
|
3.70 Scores on a scale
Standard Deviation 1.97
|
4.14 Scores on a scale
Standard Deviation 1.49
|
PRIMARY outcome
Timeframe: 30 months (from when the first Treatment Group subject enrolled to when the last Treatment Group subject completed the study)Population: All enrolled Treatment Group subjects
At each study visit following the baseline assessment at Visit 1, subjects were questioned if any changes in their medical status or condition has occurred since their previous visit. If the subject experienced a change that was an adverse event, an Adverse Event Form was completed by the site. The number of Treatment Group subjects that experienced at least one study-related adverse event is reported here.
Outcome measures
| Measure |
Treatment Group
n=18 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Number of Subjects That Experienced at Least One Study-Related Adverse Event
|
8 Participants
|
—
|
SECONDARY outcome
Timeframe: Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))Population: Per Protocol Set
All subjects were asked to complete daily diaries to track their average pain intensity during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Average Knee Pain Over the Last 24 Hours
|
3.24 score on a scale
Standard Deviation 1.52
|
4.32 score on a scale
Standard Deviation 1.34
|
SECONDARY outcome
Timeframe: Postoperative Day 0 to 28 (first 4 weeks following Total Knee Arthroplasty (TKA))Population: Per Protocol Set
All subjects were asked to complete daily diaries to track their average pain intensity at rest during the past 24 hours over a 7-day period on an 11-point numerical rating scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The average score for each diary period was calculated across subjects, and the mean score for weeks 1-4 is reported.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Average Knee Pain at Rest
|
2.86 score on a scale
Standard Deviation 1.23
|
3.48 score on a scale
Standard Deviation 1.33
|
SECONDARY outcome
Timeframe: Baseline (Visit 2a/2b), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 4 (in-hospital), Visit 6 (2-weeks post TKA), and Visit 8 (4-weeks post TKA)Population: Per Protocol Set - Data were not available for one Treatment Group subject at Visit 3 and for one Control Group subject at Visit 6.
Subjects were asked to rate their pain right now on an 11-point numerical scale where 0 represents "No Pain" and 10 represents "Pain as bad as you can imagine." The median score for each time point is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects. For Treatment Group subjects for Visits 3, 4, 6, and 8, pain right now was assessed while peripheral nerve stimulation was on for at least one Lead. For Visit 4, the score reported during the last in-hospital day was used.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Pain Right Now as Measured by the Brief Pain Inventory
Baseline
|
1.0 Scores on a scale
Interval 0.0 to 2.0
|
3.0 Scores on a scale
Interval 1.0 to 10.0
|
|
Pain Right Now as Measured by the Brief Pain Inventory
Visit 3 (Day of TKA)
|
2.0 Scores on a scale
Interval 0.0 to 8.0
|
2.0 Scores on a scale
Interval 0.0 to 10.0
|
|
Pain Right Now as Measured by the Brief Pain Inventory
Visit 4 (In-Hospital)
|
2.0 Scores on a scale
Interval 1.0 to 6.0
|
3.5 Scores on a scale
Interval 0.0 to 7.0
|
|
Pain Right Now as Measured by the Brief Pain Inventory
Visit 6 (2-weeks Post-TKA)
|
2.0 Scores on a scale
Interval 1.0 to 8.0
|
3.0 Scores on a scale
Interval 0.0 to 6.0
|
|
Pain Right Now as Measured by the Brief Pain Inventory
Visit 8 (4-weeks Post-TKA)
|
1.0 Scores on a scale
Interval 0.0 to 3.0
|
1.0 Scores on a scale
Interval 0.0 to 6.0
|
SECONDARY outcome
Timeframe: Visits 5-8 (weeks 1-4 post-Total Knee Arthroplasty (TKA))Population: Per Protocol Set - Data were not available for one Control Group subject at Visits 6-8.
Subjects recorded the amount/type of analgesics used in daily diaries. Narcotic usage was converted into morphine milligram equivalents (MME). Diaries were collected at various visits and were translated into post-operative days. The average MME was calculated for each subject for the first 28 days (4 weeks) following surgery, and the median of these averages across subjects was determined. If subjects had ceased opioid use (per the Recovery Milestones log), then missing scores following the date of opioid cessation were replaced with 0 MME. If diary entries were missing but the subject had not yet reported opioid cessation, then the missing value was replaced with the mean usage of the available days for the corresponding week. Subjects missing data from one or more entire diaries (i.e., weeks) and had not yet reported opioid cessation by the date of any missing diary were not included in this analysis.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=14 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Amount of Analgesic Usage
Visit 5 (1-week Post-TKA)
|
29.9 MME
Interval 3.2 to 49.3
|
31.4 MME
Interval 0.0 to 107.1
|
|
Amount of Analgesic Usage
Visit 6 (2-weeks Post-TKA)
|
21.4 MME
Interval 2.1 to 31.1
|
22.5 MME
Interval 0.0 to 88.8
|
|
Amount of Analgesic Usage
Visit 7 (3-weeks Post-TKA)
|
13.6 MME
Interval 1.1 to 20.0
|
17.1 MME
Interval 0.0 to 69.6
|
|
Amount of Analgesic Usage
Visit 8 (4-weeks Post-TKA)
|
11.4 MME
Interval 0.0 to 20.7
|
2.9 MME
Interval 0.0 to 47.1
|
|
Amount of Analgesic Usage
Average Across Visits 5-8
|
19.1 MME
Interval 2.1 to 26.8
|
16.8 MME
Interval 0.13 to 75.0
|
SECONDARY outcome
Timeframe: Baseline (Visit 2a/2b), Visits 4-11 (in-hospital days through 12-months post-Total Knee Arthroplasty (TKA))Population: Per Protocol Set - Data were not available for one Treatment Group subject at Visit 6 and Visit 11. Data were not available for the following Control Group subjects: one at Visits 5, 6, 7, and 9, and three at Visits 10 and 11.
Throughout the study, subjects were asked if they experienced any side effects related to opioid pain medications. The occurrences of these side effects were recorded and were not considered Adverse Events. The number of subjects that experienced at least one opioid-related side effect at each visit is reported. Baseline is considered Visit 2a (Lead Placement) for Treatment Group subjects and Visit 2b for Control Group subjects.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Number of Subjects That Experienced at Least One Opioid-Related Side Effect
Baseline
|
0 Participants
|
0 Participants
|
|
Number of Subjects That Experienced at Least One Opioid-Related Side Effect
Visit 4 (In-Hospital)
|
3 Participants
|
7 Participants
|
|
Number of Subjects That Experienced at Least One Opioid-Related Side Effect
Visit 5 (1-week Post-TKA)
|
3 Participants
|
9 Participants
|
|
Number of Subjects That Experienced at Least One Opioid-Related Side Effect
Visit 6 (2-weeks Post-TKA)
|
3 Participants
|
8 Participants
|
|
Number of Subjects That Experienced at Least One Opioid-Related Side Effect
Visit 7 (3-weeks Post-TKA)
|
2 Participants
|
6 Participants
|
|
Number of Subjects That Experienced at Least One Opioid-Related Side Effect
Visit 8 (4-weeks Post-TKA)
|
1 Participants
|
4 Participants
|
|
Number of Subjects That Experienced at Least One Opioid-Related Side Effect
Visit 9 (2-months Post-TKA)
|
0 Participants
|
0 Participants
|
|
Number of Subjects That Experienced at Least One Opioid-Related Side Effect
Visit 10 (3-months Post-TKA)
|
0 Participants
|
0 Participants
|
|
Number of Subjects That Experienced at Least One Opioid-Related Side Effect
Visit 11 (12-months Post-TKA)
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Visit 1 (Baseline), Visit 4 (In-Hospital), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks Post-TKA)Population: Per Protocol Set - Data were not available for the following Control Group subjects: one at Visit 1 (subject was unable to complete test), three at Visit 4 (two subjects were unable to complete test), and one at Visit 6.
Subjects began this test from a seated position in a standard chair and were timed while they stood up, walked to a marked point 10 feet away (at a normal, safe pace), returned to the chair, and sat down. Timed Up and Go (TUG) test times are expected to be greater immediately after surgery as compared to baseline.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Timed Up and Go (TUG) Test
Time at Visit 8 (4-weeks Post-TKA)
|
10.68 seconds
Interval 6.59 to 17.07
|
10.38 seconds
Interval 6.9 to 40.68
|
|
Timed Up and Go (TUG) Test
Time at Visit 1 (Baseline)
|
12.44 seconds
Interval 4.82 to 13.7
|
10.25 seconds
Interval 7.0 to 26.24
|
|
Timed Up and Go (TUG) Test
Time at Visit 4 (In-Hospital)
|
41.80 seconds
Interval 11.13 to 141.32
|
42.22 seconds
Interval 13.81 to 82.37
|
|
Timed Up and Go (TUG) Test
Time at Visit 6 (2-weeks Post-TKA)
|
14.28 seconds
Interval 7.63 to 32.36
|
15.93 seconds
Interval 7.39 to 56.0
|
SECONDARY outcome
Timeframe: Visit 1 (Baseline), Visit 6 (2-weeks Post-Total Knee Arthroplasty (TKA)), Visit 8 (4-weeks post-TKA)Population: Per Protocol Set - Data were not available for one Control Group subject at Visit 6.
The total distance that a subject could walk in 6 minutes was recorded, and subjects unable to walk at all were given a score of 0 meters. The median distance was then determined across subjects. 6 Minute Walk Test distances are expected to be reduced immediately after surgery as compared to baseline.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Six Minute Walk Test (6MWT)
Visit 1 (Baseline)
|
458.5 meters
Interval 320.0 to 555.0
|
351.3 meters
Interval 0.0 to 504.0
|
|
Six Minute Walk Test (6MWT)
Visit 6 (2-weeks Post-TKA)
|
280.0 meters
Interval 150.0 to 504.7
|
281.0 meters
Interval 0.0 to 680.2
|
|
Six Minute Walk Test (6MWT)
Visit 8 (4-weeks Post-TKA)
|
410.0 meters
Interval 270.0 to 693.0
|
329.0 meters
Interval 0.0 to 518.9
|
SECONDARY outcome
Timeframe: Visit 1 (Baseline), Visit 3 (Day of Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 10 (3-months post-TKA), and Visit 11 (12-months post-TKA)Population: Per Protocol Set - Data were not available for one Treatment Group subject at Visit 11. Data were not available for the following Control Group subjects: three at Visit 3, one at Visit 6, three at Visit 10, and two at Visit 11.
The Western Ontario McMaster University Osteoarthritis Index (WOMAC) questionnaire consists of 24 items that evaluate pain, stiffness, and physical functional disability. Each item is scored on an 11-point numerical rating scale from 0 to 10, where higher scores indicate greater pain, stiffness, and disability. For each subject, the scores from each of the 24 items were summed to calculate the subject's total score, with a minimum score of 0 and a maximum score of 240. The mean total score was then calculated across subjects for each time point.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Visit 10 (3-months Post-TKA)
|
22.86 score on a scale
Standard Deviation 22.13
|
29.38 score on a scale
Standard Deviation 21.05
|
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Visit 1 (Baseline)
|
87.00 score on a scale
Standard Deviation 30.34
|
111.31 score on a scale
Standard Deviation 38.78
|
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Visit 3 (Day of TKA)
|
68.71 score on a scale
Standard Deviation 47.87
|
99.23 score on a scale
Standard Deviation 51.25
|
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Visit 6 (2-weeks Post-TKA)
|
58.57 score on a scale
Standard Deviation 33.24
|
81.13 score on a scale
Standard Deviation 38.98
|
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Visit 8 (4-weeks Post-TKA)
|
40.29 score on a scale
Standard Deviation 26.56
|
51.94 score on a scale
Standard Deviation 30.83
|
|
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
Visit 11 (12-months Post-TKA)
|
4.83 score on a scale
Standard Deviation 4.36
|
12.79 score on a scale
Standard Deviation 20
|
SECONDARY outcome
Timeframe: Visits 3-11 (Day of Total Knee Arthroplasty (TKA) through 12-months post-TKA)Population: Per Protocol Set: Data were not available for one Treatment Group subject at Visit 11. Data were not available for the following Control Group subjects: one at Visit 4, one at Visit 6, one at Visit 9, three at Visit 10, and two at Visit 11.
The Patient Global Impression of Change (PGIC) asks subjects to rate their improvement with treatment on a 7-point scale ranging from "very much worse" to "very much improved" as compared to before their knee replacement surgery. The subjects combine all the components of their experience into one overall score. Ratings of Much- or Very Much Improved are considered "Meaningful Improvements"; similarly, ratings of Much- or Very Much Worse are categorized as "Meaningfully Worse." Ratings of Minimally Improved, No Change, or Minimally Worse are considered "Minimal or No Change."
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 3 (Day of TKA) · Meaningful Improvement
|
0 Participants
|
1 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 3 (Day of TKA) · Minimal or No Change
|
5 Participants
|
14 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 3 (Day of TKA) · Meaningfully Worse
|
2 Participants
|
1 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 4 (In-Hospital) · Meaningful Improvement
|
1 Participants
|
4 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 4 (In-Hospital) · Minimal or No Change
|
5 Participants
|
9 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 4 (In-Hospital) · Meaningfully Worse
|
1 Participants
|
2 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 5 (1-week Post-TKA) · Meaningful Improvement
|
2 Participants
|
3 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 5 (1-week Post-TKA) · Minimal or No Change
|
3 Participants
|
11 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 5 (1-week Post-TKA) · Meaningfully Worse
|
2 Participants
|
2 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 6 (2-weeks Post-TKA) · Meaningful Improvement
|
2 Participants
|
3 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 6 (2-weeks Post-TKA) · Minimal or No Change
|
3 Participants
|
11 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 6 (2-weeks Post-TKA) · Meaningfully Worse
|
2 Participants
|
1 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 7 (3-weeks Post-TKA) · Meaningful Improvement
|
2 Participants
|
3 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 7 (3-weeks Post-TKA) · Minimal or No Change
|
3 Participants
|
12 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 7 (3-weeks Post-TKA) · Meaningfully Worse
|
2 Participants
|
1 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 8 (4-weeks Post-TKA) · Meaningful Improvement
|
2 Participants
|
6 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 8 (4-weeks Post-TKA) · Minimal or No Change
|
3 Participants
|
9 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 8 (4-weeks Post-TKA) · Meaningfully Worse
|
2 Participants
|
1 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 9 (2-months Post-TKA) · Meaningful Improvement
|
4 Participants
|
8 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 9 (2-months Post-TKA) · Minimal or No Change
|
3 Participants
|
7 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 9 (2-months Post-TKA) · Meaningfully Worse
|
0 Participants
|
0 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 10 (3-months Post-TKA) · Meaningful Improvement
|
6 Participants
|
9 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 10 (3-months Post-TKA) · Minimal or No Change
|
1 Participants
|
4 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 10 (3-months Post-TKA) · Meaningfully Worse
|
0 Participants
|
0 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 11 (12-months Post-TKA) · Meaningful Improvement
|
6 Participants
|
12 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 11 (12-months Post-TKA) · Minimal or No Change
|
0 Participants
|
2 Participants
|
|
Number of Subjects Reporting Meaningful Improvement, Minimal or No Change, or Meaningful Worsening on the Patient Global Impression of Change (PGIC) Survey
Visit 11 (12-months Post-TKA) · Meaningfully Worse
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Visit 1 (Baseline), Visit 8 (4 weeks post-Total Knee Arthroplasty (TKA)), Visit 10 (3-months Post-TKA)Population: Per Protocol Set - Data were not available for three Control Group subjects at Visit 10.
The Pain Catastrophizing Scale (PCS) questionnaire has 13 questions that assess rumination, magnification, and helplessness. Subjects are asked to think back on painful experiences in the past and reflect on how often they had specific thoughts or feelings. Each of the 13 questions is scored on a 5-point scale where 0 represents "not at all," and 4 represents "all the time." The scores from each question were summed for each subject to provide a total PCS score, with a possible range from 0 to 52 with higher scores indicating a greater tendency to catastrophize pain (i.e. a higher score indicates a worse outcome). The median scores were then calculated across all subjects.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Pain Catastrophizing Scale (PCS)
Visit 1 (Baseline)
|
7 score on a scale
Interval 0.0 to 13.0
|
7 score on a scale
Interval 0.0 to 34.0
|
|
Pain Catastrophizing Scale (PCS)
Visit 8 (4-weeks Post-TKA)
|
6 score on a scale
Interval 0.0 to 14.0
|
4 score on a scale
Interval 0.0 to 19.0
|
|
Pain Catastrophizing Scale (PCS)
Visit 10 (3-months Post-TKA)
|
1 score on a scale
Interval 0.0 to 13.0
|
0 score on a scale
Interval 0.0 to 15.0
|
SECONDARY outcome
Timeframe: From Day of Surgery through completion of milestone or 12-months from Day of Surgery, whichever came firstPopulation: Per Protocol Set- Treatment Group: Data were not available for: 1 subject in "walked without assistive device", 1 in "cleared to drive". 1 subject did not cease opioids during the study. 5 subjects were retired and did not work. Control Group: Data were not collected for: 3 in "walked without assistive device", 2 in "able to climb stairs", 1 in "cleared to drive", 1 in "opioid cessation" (2 more did not cease opioids during the study). 9 subjects were retired and did not work.
Participants were queried at each visit from the date of their Total Knee Arthroplasty (TKA) until they met specific, post-surgical recovery milestones. Participants were queried up through the time at which they met each milestone or through their completion of the study, whichever came first (up to twelve months post-surgery). For each milestone, the median number of days between the date of TKA and date to achieve the milestone was calculated.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Pain controlled without nerve block
|
3 days
Interval 1.0 to 5.0
|
2 days
Interval 1.0 to 9.0
|
|
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Walked with assistive device
|
0 days
Interval 0.0 to 1.0
|
1 days
Interval 0.0 to 1.0
|
|
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Walked without assistive device
|
24 days
Interval 2.0 to 52.0
|
16 days
Interval 2.0 to 107.0
|
|
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Walked 30 meters
|
1 days
Interval 0.0 to 16.0
|
4 days
Interval 0.0 to 28.0
|
|
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Able to climb flight of stairs
|
1 days
Interval 0.0 to 10.0
|
13 days
Interval 1.0 to 251.0
|
|
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Met hospital discharge criteria
|
1 days
Interval 0.0 to 3.0
|
1 days
Interval 0.8 to 3.0
|
|
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Discharged from hospital
|
1 days
Interval 0.0 to 3.0
|
1 days
Interval 0.9 to 4.0
|
|
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Cleared to drive
|
21 days
Interval 14.0 to 62.0
|
21 days
Interval 15.0 to 71.0
|
|
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Returned to work
|
9 days
Interval 1.0 to 17.0
|
20 days
Interval 7.0 to 56.0
|
|
Time to Meet Recovery Milestones up to Twelve Months Post-Total Knee Arthroplasty (TKA)
Cessation of all opioid medications
|
37 days
Interval 10.0 to 61.0
|
28 days
Interval 6.0 to 336.0
|
SECONDARY outcome
Timeframe: Visit 8 (4-weeks post-total knee arthroplasty (TKA))Population: Per Protocol Set
Subjects completed a sponsor-developed survey with questions pertaining to their feelings about the treatment they received following total knee arthroplasty (TKA) surgery. Treatment Group subjects were asked to report on their experience using the SPRINT Beta Stimulation System as a method for managing post-surgical pain. Depending on the question, subjects were asked to indicate their agreement with the question (strongly disagree, agree, neutral, disagree, strongly disagree), their comfort with the therapy (very uncomfortable, a little bit uncomfortable, fairly comfortable, very comfortable), or when pain relief was felt (immediately, a few minutes later, a few hours later, more than a day later or never). Responses are presented for Treatment Group subjects for key groups of questions related to the therapy whereby answer options are considered affirmative for strongly agree/agree, very easy/easy, very comfortable/comfortable.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Subject Satisfaction Survey
Tolerated Lead placement with some or no discomfort
|
7 Participants
|
—
|
|
Subject Satisfaction Survey
Reported stimulation felt comfortable/soothing
|
5 Participants
|
—
|
|
Subject Satisfaction Survey
Reported immediate pain relief (0-5 minutes)
|
4 Participants
|
—
|
|
Subject Satisfaction Survey
Would recommend therapy to a friend
|
7 Participants
|
—
|
|
Subject Satisfaction Survey
Would want to receive again if having another TKA
|
7 Participants
|
—
|
|
Subject Satisfaction Survey
Prefer stimulation therapy to pain medication use
|
7 Participants
|
—
|
|
Subject Satisfaction Survey
Wanted stimulation for longer time period before TKA surgery
|
1 Participants
|
—
|
|
Subject Satisfaction Survey
Wanted stimulation for longer time period after TKA surgery
|
1 Participants
|
—
|
SECONDARY outcome
Timeframe: Visit 5 (1-week post-Total Knee Arthroplasty (TKA)), Visit 6 (2-weeks post-TKA), Visit 7 (3-weeks post-TKA), Visit 8 (4-weeks post-TKA), Visit 9 (2-months post-TKA), and Visit 10 (3-months post-TKA)Population: Per Protocol Set - Data were not available for the following Control Group subjects: one at Visit 6, two Visit 9, and three at Visit 10.
Following discharge after total knee arthroplasty (TKA) surgery, subjects were asked to report how many physical therapy sessions they attended since the previous study visit. The median number of physical therapy sessions attended is reported for each group at each time point.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=16 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty
Visit 10 (3-months Post-TKA)
|
8 Count of visits
Interval 0.0 to 12.0
|
6 Count of visits
Interval 0.0 to 12.0
|
|
Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty
Visit 5 (1-week Post-TKA)
|
2 Count of visits
Interval 1.0 to 3.0
|
2 Count of visits
Interval 1.0 to 10.0
|
|
Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty
Visit 6 (2-weeks Post-TKA)
|
3 Count of visits
Interval 2.0 to 5.0
|
3 Count of visits
Interval 2.0 to 14.0
|
|
Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty
Visit 7 (3-weeks Post-TKA)
|
2 Count of visits
Interval 1.0 to 3.0
|
3 Count of visits
Interval 0.0 to 5.0
|
|
Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty
Visit 8 (4-weeks Post-TKA)
|
2 Count of visits
Interval 1.0 to 3.0
|
2 Count of visits
Interval 0.0 to 5.0
|
|
Number of Physical Therapy Sessions Attended Following Total Knee Arthroplasty
Visit 9 (2-months Post-TKA)
|
9 Count of visits
Interval 4.0 to 12.0
|
5 Count of visits
Interval 0.0 to 14.0
|
SECONDARY outcome
Timeframe: Visit 4 (In-Hospital), Visit 6 (2-weeks post-Total Knee Arthroplasty (TKA)), and Visit 8 (4-weeks Post-TKA)Population: Per Protocol Set - Treatment Group. Data were not available for the femoral or sciatic Leads for one subject at Visit 4 and two subjects at Visit 6. One subject at Visits 4, 6, 8 did not have a sciatic Lead in place.
The hours of usage were recorded for each Lead (femoral and sciatic) from the SPRINT Beta stimulator throughout the study to assess the level of subject compliance with the peripheral nerve stimulation therapy. Treatment Group subjects were asked to use the device for up to 24 hrs each day. The stimulator provided the cumulative number of hours in use since the device was activated. For each timepoint for Treatment Group participants (subjects who received stimulation therapy), the median cumulative number of hours of use for each lead is presented for each timepoint.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Subject's Use of Device (Compliance)
Visit 4 (In-Hospital): Femoral Lead
|
79 hours
Interval 31.0 to 207.0
|
—
|
|
Subject's Use of Device (Compliance)
Visit 4 (In-Hospital): Sciatic Lead
|
73 hours
Interval 28.0 to 200.0
|
—
|
|
Subject's Use of Device (Compliance)
Visit 6 (2-weeks Post-TKA): Femoral Lead
|
358 hours
Interval 190.0 to 519.0
|
—
|
|
Subject's Use of Device (Compliance)
Visit 6 (2-weeks Post-TKA): Sciatic Lead
|
373.5 hours
Interval 269.0 to 429.0
|
—
|
|
Subject's Use of Device (Compliance)
Visit 8 (4-weeks Post-TKA): Femoral Lead
|
646 hours
Interval 266.0 to 744.0
|
—
|
|
Subject's Use of Device (Compliance)
Visit 8 (4-weeks Post-TKA): Sciatic Lead
|
633 hours
Interval 271.0 to 673.0
|
—
|
SECONDARY outcome
Timeframe: 1-week post-Total Knee Arthroplasty (TKA)Population: Per Protocol Set - Data were not available for three Control Group subjects.
Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. Questions regarding experience with in-hospital pain management are reported below.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=13 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)
During this hospital stay, how often was your pain well controlled? · Never
|
0 Participants
|
0 Participants
|
|
Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)
During this hospital stay, how often was your pain well controlled? · Sometimes
|
1 Participants
|
3 Participants
|
|
Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)
During this hospital stay, how often was your pain well controlled? · Usually
|
3 Participants
|
4 Participants
|
|
Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)
During this hospital stay, how often was your pain well controlled? · Always
|
3 Participants
|
6 Participants
|
|
Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)
During hospital stay, how often did hospital staff do everything they could to help with your pain? · Never
|
0 Participants
|
0 Participants
|
|
Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)
During hospital stay, how often did hospital staff do everything they could to help with your pain? · Sometimes
|
0 Participants
|
1 Participants
|
|
Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)
During hospital stay, how often did hospital staff do everything they could to help with your pain? · Usually
|
1 Participants
|
2 Participants
|
|
Inpatient Pain Management Experience Survey (Pain Management During Hospital Stay)
During hospital stay, how often did hospital staff do everything they could to help with your pain? · Always
|
6 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: 1-week post-Total Knee Arthroplasty (TKA)Population: Per Protocol - Data were not available for three Control Group subjects
Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The number of subjects that responded affirmatively to the following question are reported below: "During this hospital stay, did you need medicine for pain?"
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=13 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Inpatient Pain Management Experience Survey (Pain Medicine During Hospital Stay)
|
6 Participants
|
13 Participants
|
SECONDARY outcome
Timeframe: 1-week post-Total Knee Arthroplasty (TKA)Population: Per Protocol Set - Data were not available for three Control Group subjects.
Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. The question regarding discharge location following hospital stay is reported below.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=13 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Inpatient Pain Management Experience Survey (Discharge Facility)
Own home
|
7 Participants
|
11 Participants
|
|
Inpatient Pain Management Experience Survey (Discharge Facility)
Someone else's home
|
0 Participants
|
1 Participants
|
|
Inpatient Pain Management Experience Survey (Discharge Facility)
Another healthcare facility
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: 1-week post-Total Knee Arthroplasty (TKA))Population: Per Protocol Set - Data were not available for three Control Group subjects.
Subjects completed a survey comprised of a subset of questions from the Hospital Consumer Assessment of Healthcare Providers and Systems to assess subject satisfaction with pain management during their time in the hospital for total knee arthroplasty surgery. As part of this survey, subjects were asked to rate their hospital stay on an 11-point numerical rating scale where 0 represents "worst hospital possible" and 10 represents "best hospital possible." The median score for each group is reported.
Outcome measures
| Measure |
Treatment Group
n=7 Participants
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=13 Participants
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Inpatient Pain Management Experience Survey (Overall Rating of Hospital)
|
10 score on a scale
Interval 8.0 to 10.0
|
10 score on a scale
Interval 7.0 to 10.0
|
Adverse Events
Treatment Group
Control Group
Serious adverse events
| Measure |
Treatment Group
n=18 participants at risk
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=23 participants at risk
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate Cancer
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Cardiac disorders
Acute Myopericarditis
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
Pain at TKA Surgical Site
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Surgical and medical procedures
Adverse Drug Reaction During TKA
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Gastrointestinal disorders
Acute Pancreatitis and Gall Stones
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Infections and infestations
Sepsis due to Urinary Tract Infection
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
Other adverse events
| Measure |
Treatment Group
n=18 participants at risk
Subjects in the Treatment Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects had at least one Lead placed in their affected leg prior to TKA and used the SPRINT Beta System to receive electrical stimulation therapy in addition to the standard of care.
|
Control Group
n=23 participants at risk
Subjects in the Control Group were consented, scheduled to undergo a unilateral total knee arthroplasty (TKA), and met all eligibility criteria prior to randomization. These subjects did not undergo Lead placement, and they received the standard of care following TKA.
|
|---|---|---|
|
Skin and subcutaneous tissue disorders
Skin irritation at bandage site
|
11.1%
2/18 • Number of events 2 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
—
0/0 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Skin and subcutaneous tissue disorders
Skin irritation or bruising at pad and/or Lead exit site
|
22.2%
4/18 • Number of events 4 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
—
0/0 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Skin and subcutaneous tissue disorders
Generalized itching
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Skin and subcutaneous tissue disorders
Discharge from TKA surgical incision
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Skin and subcutaneous tissue disorders
Burning sensation and swelling of knee
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Skin and subcutaneous tissue disorders
Ulcers
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Skin and subcutaneous tissue disorders
Wound dehiscence
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
New hip pain
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
Pain at TKA surgical site
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
Worsening knee pain
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
Ankylosis of knee
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
Knee effusion
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasming
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
Sciatica and Piriformis Syndrome
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
Thumb pain
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Musculoskeletal and connective tissue disorders
Shoulder pain
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Eye disorders
Worsening cataract
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 2 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Cardiac disorders
Elevated blood pressure
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Renal and urinary disorders
Urinary tract infection
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchial asthma
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/18 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Ear and labyrinth disorders
Hearing loss
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
4.3%
1/23 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Product Issues
Soreness after Lead placement
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
—
0/0 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Product Issues
Shocking at Lead site
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
—
0/0 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
Nervous system disorders
Restless Leg Syndrome flare up
|
5.6%
1/18 • Number of events 1 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
0.00%
0/23 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
|
General disorders
Illness
|
11.1%
2/18 • Number of events 2 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
13.0%
3/23 • Number of events 5 • Each participant enrolled was assessed for adverse events from the time of informed consent through the 12-month follow up visit. The total assessment period was approximately 13 months for each participant.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place